⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MGNX News
MacroGenics, Inc.
Incyte Japan annonce l’autorisation de Zynyz ® (rétifanlimab) pour le traitement de première intention du cancer anal avancé
businesswire.com
INCY
MGNX
Breast Cancer Drugs Market to Reach USD 57.1 Billion by 2031 as Precision Oncology and Targeted Therapies Redefine Treatment Outcomes
prnewswire.com
NVS
LLY
AZN
MRK
ABBV
BMED
MGNX
VALVOSOFT®, the First Non-Invasive Treatment for Severe Symptomatic Aortic Stenosis (sSAS) from Cardiawave Receives CE Marking
businesswire.com
MGNX
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference
globenewswire.com
MGNX
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress
globenewswire.com
MGNX
MacroGenics to Participate in the Stifel 2025 Healthcare Conference
globenewswire.com
MGNX